title: Bleeding related to disturbed fibrinolysis.
abstract: The components and reactions of the fibrinolysis system are well understood. The pathway has fewer reactants and interactions than coagulation, but the generation of a complete quantitative model is complicated by the need to work at the solid-liquid interface of fibrin. Diagnostic tools to detect disease states due to malfunctions in the fibrinolysis pathway are also not so well developed as is the case with coagulation. However, there are clearly a number of inherited or acquired pathologies where hyperfibrinolysis is a serious, potentially life-threatening problem and a number of antifibrinolytc drugs are available to treat hyperfibrinolysis. These topics will be covered in the following review.
authors.affiliation: Department of Medical Biochemistry, Semmelweis University, Budapest, Hungary.
authors.forename: Krasimir
authors.initials: K
authors.lastname: Kolev
authors.affiliation: Biotherapeutics Group, National Institute for Biological Standards and Control, South Mimms, UK. colin.longstaff@nibsc.org.
authors.forename: Colin
authors.initials: C
authors.lastname: Longstaff
mesh_terms: D000818:Animals; D000933:Antifibrinolytic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects; D025861:Blood Coagulation Disorders, Inherited / Q000097:blood / Q000150:complications / Q000209:etiology; D001780:Blood Coagulation Tests; D005342:Fibrinolysis; D006470:Hemorrhage / Q000097:blood* / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000150:complications; D008239:Lysine / Q000031:analogs & derivatives / Q000627:therapeutic use; D010641:Phenotype; D015843:Serpins / Q000378:metabolism; D015912:Thrombolytic Therapy
chemical_list: D000933:Antifibrinolytic Agents; D015843:Serpins; D008239:Lysine
keywords: acute promyelocytic leukaemia; antiplasmin; bleeding disorders; fibrinolysis; plasminogen activator inhibitor type 1